Hugo Hok Him Pui

Comparisons of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9I) versus Ezetimibe on Major Adverse Cardiovascular Events Amongst Patients with Dyslipidaemia: A Population-Based Study

B. Leung, Lifang Li, Jiandong Zhou, 2023, medRxiv.